2023年12月13日,备受瞩目的《肿瘤学年鉴》(Annals of Oncology,影响因子:50.5)期刊在线发布了2023版ESMO早期乳腺癌临床实践指南——“Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up”。本期(...
[7] Curigliano G, Castelo-Branco L, Gennari A, et al. ESMO Metastatic Breast Cancer Living Guidelines, v1.1 May 2023. https://www.esmo.org/living-quidelines/esmo-metastatic-breast- cancer-living-quideline [8] Modi S, Jacot ...
[8] G Curigliano, L Castelo-Branco, A Gennari, et al. ESMO Metastatic Breast Cancer Living Guidelines, v1.1 May 2023. [9] Mosele F, Deluche E, Lusque A, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023...
HER2阳性转移性乳腺癌中,基于DESTINY-Breast03研究(简称DB03研究)卓越疗效,本次ESMO指南在线更新最重要的是在非活动性脑转移患者的二线治疗中将德曲妥珠单抗作为唯一推荐方案,而恩美曲妥珠单抗则被移至三线治疗,这是继2023 v1 NCCN[2]后又一国际权威指南将德曲妥珠单抗作为HER2阳性晚期乳腺癌二线唯一方案。此外,2022年...
[4]Curigliano G,Castelo-Branco L,Gennari A,et al.ESMO Metastatic Breast Cancer Living Guidelines,v1.1 May 2023. [5]Verma S,et al.Trastuzumab emtansine for HER2-positive advanced breast cancer.N Engl J Med.2012,367(19):1783-9.
PusztaiL,ReganMM,SparanoJ,SpanicT,SwainS,TjulandinS,ToiM,TrapaniD,TuttA,XuB,CuriglianoG,HarbeckN;ESMOGuidelinesCommittee.Earlybreastcancer:ESMOClinicalPracticeGuidelinefordiagnosis,treatmentandfollow-upt.AnnOncol.2023 Dec8:S0923-7534(23)05104-9.doi:10.1016/j.annonc.2023.11.016. 下载文档 收藏 分享...
2024年,ESMO转移性乳腺癌在线指南v. 1.1版(ESMO Metastatic Breast Cancer Living Guideline V. 1.1)将戈沙妥珠单抗(SG)治疗转移性三阴性乳腺癌(mTNBC)的ESMO临床获益量表(ESMO-MCBS)评分,由既往的4分调整为最高等级5分[1-2];目前,SG是mTNBC二线治疗唯一的首选推荐(I类证据,推荐等级A)。
2024年,ESMO转移性乳腺癌在线指南v. 1.1版(ESMO Metastatic Breast Cancer Living Guideline V. 1.1)将戈沙妥珠单抗(SG)治疗转移性三阴性乳腺癌(mTNBC)的ESMO临床获益量表(ESMO-MCBS)评分,由既往的4分调整为最高等级5分[1-2];目前,SG是mTNBC二线治疗唯一的首选推荐(I类证据,推荐等级A)。
Gibson I, et al. Real-world outcomes in patients with HR-positive/HER2-negative metastatic breast cancer and germline/tumour BRCA mutations receiving 1st-line CDK4/6 inhibitors plus endocrine therap[EB/OL]. [2024-09-11]. https://oncologypro.esmo.org/meeting-resources/esmo-breast-cancer-2023....
同时新版ESMO在线指南也针对新纳入的治疗方案进行ESMO-MCBS评分,基于DESTINY-Breast04 PFS及OS的双重获益,其疗效评分达到最高的4分,为临床决策提供了更多的参考。 点击图片查看大图 点击图片查看大图 参考文献 上下滑动查看更多内容 [1]ESMO Metastatic Breast Cancer Living Guidelines, v1.1 May 2023.https://www.e...